Globus Medical Q1 EPS Forecast Increased by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research lifted their Q1 2028 earnings estimates for Globus Medical in a research report issued to clients and investors on Tuesday, March 31st. Zacks Research analyst Team now forecasts that the medical device company will earn $1.20 per share for the quarter, up from their previous forecast of $1.19. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share.

Several other equities research analysts have also recently commented on the company. Piper Sandler reaffirmed an “overweight” rating and set a $115.00 target price (up from $90.00) on shares of Globus Medical in a research note on Thursday, January 8th. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research note on Tuesday, December 30th. Wells Fargo & Company upgraded Globus Medical to a “strong-buy” rating in a report on Wednesday, March 18th. Truist Financial set a $115.00 price objective on shares of Globus Medical in a research report on Wednesday, February 25th. Finally, Needham & Company LLC lifted their price objective on shares of Globus Medical from $112.00 to $114.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $104.36.

Globus Medical Trading Down 0.0%

GMED stock opened at $87.72 on Thursday. The firm has a market cap of $11.86 billion, a PE ratio of 22.26, a price-to-earnings-growth ratio of 2.05 and a beta of 1.09. The stock has a 50-day moving average price of $88.88 and a 200-day moving average price of $80.81. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40.

Globus Medical (NYSE:GMED) last released its earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The business had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. During the same quarter in the previous year, the business earned $0.84 earnings per share. Globus Medical’s revenue for the quarter was up 25.7% on a year-over-year basis.

Hedge Funds Weigh In On Globus Medical

Large investors have recently modified their holdings of the company. Hsbc Holdings PLC acquired a new stake in Globus Medical in the 4th quarter valued at $2,254,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Globus Medical by 52.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 11,738 shares of the medical device company’s stock valued at $1,025,000 after purchasing an additional 4,042 shares in the last quarter. Corient Private Wealth LLC boosted its position in shares of Globus Medical by 7.1% during the fourth quarter. Corient Private Wealth LLC now owns 51,372 shares of the medical device company’s stock valued at $4,487,000 after buying an additional 3,390 shares during the last quarter. MidFirst Bank bought a new stake in Globus Medical during the fourth quarter worth $354,000. Finally, Pacer Advisors Inc. grew its holdings in Globus Medical by 20.4% during the fourth quarter. Pacer Advisors Inc. now owns 33,177 shares of the medical device company’s stock worth $2,897,000 after buying an additional 5,617 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors.

Insider Activity at Globus Medical

In other Globus Medical news, Director Leslie V. Norwalk sold 2,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the transaction, the director owned 10,419 shares in the company, valued at approximately $1,053,360.90. This represents a 16.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 35,594 shares of company stock valued at $3,332,253 in the last three months. Corporate insiders own 18.51% of the company’s stock.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks raised its Q1 2028 EPS forecast to $1.20 (from $1.19) and reiterated a “Strong‑Buy” rating — a direct, recent upgrade to near‑term earnings expectations that can boost investor confidence. MarketBeat GMED
• Positive Sentiment: Multiple small upward revisions across quarters (Q1–Q3 2026, Q1–Q3 2027) and fiscal years (FY2026, FY2027, FY2028) — including FY2026 to $4.42, FY2027 to $4.67 and FY2028 to $5.19 — suggest Zacks is modeling modestly stronger revenue/profit trends over the next several years. This broad-based upgrade pattern is a constructive signal for growth expectations. MarketBeat GMED
• Neutral Sentiment: Valuation and technical backdrop: GMED trades with a market cap ~ $11.9B and a P/E ~22x; the stock sits near its 50‑day moving average (~$88.9) above the 200‑day (~$80.8). These factors moderate how quickly upgrades translate into price moves — investors will watch upcoming results and guidance for confirmation. MarketBeat GMED

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.